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LETTER TO THE EDITOR
ANTIBODIES TO THE 60 AND 65 KDA HEAT-SHOCK
PROTEINS AND RISK OF PERIPHERAL ARTERY
DISEASE
Marcus Franck, Gary L. Norman, Carlos Alberto von Muhlen, Betina Volbrech,
Maria Otília Cerveira, and Henrique Luiz Staub
Autoimmunity may be involved in atherogenesis. Beta2-
glycoprotein I (beta2-gpI) and heat-shock proteins (Hsp) are
found in the atherosclerotic plaque.1,2 Our group has recently
looked at the humoral response to these atheromatous com-
ponents. Uniformly, IgA antibodies to beta2-gpI were asso-
ciated with an increase in the risk of cerebral ischemia,3 myo-
cardial infarction,4 and peripheral artery disease (PAD).5
In turn, IgG antibodies to the 60 kilodalton (kDa) hu-
man Hsp and to the 65 kDa Mycobacterium bovis Hsp be-
haved as risk factors for cerebral ischemia,3 but not for myo-
cardial infarction.6 These intriguing findings led us to de-
termine whether elevated levels of IgG anti-Hsp 60 and 65
are associated with an increased risk of PAD.
Seventy-seven patients with PAD and 93 controls were
included in this case-control study. Diagnosis of PAD was
based on clinical features (intermittent claudication, critical
ischemia) and arteriographic changes (lesion, stenosis, oc-
clusion). Controls with no symptoms of PAD were recruited
from orthopedic wards. Risk factors evaluated in cases and
controls included age, sex, race, hypertension, diabetes
mellitus, smoking, and hypercholesterolemia. IgG antibod-
ies to the human f Hsp 60 and to the Mycobacteria bovis
Hsp 65 were detected by enzyme-linked immunoabsorbent
assay (INOVA Diagnostics, Inc., San Diego, USA). Samples
with optical densities above 0.5 were considered positive.
Odds ratios (OR) were calculated by logistic regression.
The mean age was 61.5 years for cases and 47.5 for con-
trols (P < .001). This age difference was adjusted by
multivariate analysis. Caucasoids (strongly) and males
(slightly) predominated in both groups. Among the known
risk factors, hypertension yielded the strongest association
with PAD (OR 12.1; 95% CI 5.8-30; P < .001). IgG anti-
Hsp 60 antibodies were detected in 6.5% of cases but not
in controls. This antibody was strongly associated with the
risk of PAD (non-adjusted OR 14.2 after Agresti correction;
95% CI 1.5-infinite; P = .02). A negative association of IgG
anti-Hsp 60 kDa with older age was obtained (OR 0.1; 95%
CI 0-0.7; P = .02). IgG anti-Hsp 60 antibodies did not asso-
ciate with any particular arteriographic pattern. The occur-
rence of IgG anti-Hsp 65 did not differ in cases and con-
trols (adjusted OR 1.3; 95% CI 0.4-4.3; P = .72).
There have been few reports on anti-Hsp 60 or 65 and
PAD. Wright et al. investigated the frequency of antibodies
to Hsp of 60, 65, and 70 kDa in cases of PAD and renal
vascular disease. Significant levels of anti-Hsp 60 antibod-
ies were detected in patients with PAD, but not in those with
renal disease. High levels of anti-Hsp 70 antibodies were
found in both groups as compared to controls.7
This risk association of IgG anti-Hsp 60 kDa with PAD
corroborates our previous findings in cerebral ischemia,3 but
differ from our results in myocardial infarction.6 As opposed
to our results on cerebral ischemia patients,3 an association
of IgG anti-Hsp 65 kDa was not confirmed in PAD patients.
In the atherogenic process, human Hsp 60, which is
highly homologous to bacterial Hsp of 65 kDa, is synthe-
sized by the endothelium as a response to cell injury.8 The
pathogenic role, if any, of anti-Hsp 60 or 65 in patients with
cerebral ischemia, coronary disease, and PAD has yet to be
clarified. Of interest, the antibody profile seems to differ in
these various groups of atherosclerotic patients. A clinical
use for these antibodies still requires confirmation. Epiphe-
nomenon or not, antibodies to Hsp 60 or 65 might repre-
sent one of the links between autoimmunity and atheroma-
tosis of the peripheral circulation.
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